India: Rotavirus vaccine reduced severe rotavirus diarrhea by 40 percent in Phase 3 study

Results from a Phase 3 efficacy study in India of the Serum Institute of India Pvt. Ltd.'s rotavirus vaccine BRV-PV (known as ROTASIIL(R)) were published in the journal Vaccine. The study showed the vaccine to be safe, well tolerated, and to provide significant efficacy against severe rotavirus gastroenteritis. In 2013, an estimated 47,100 rotavirus deaths occurred ["]

The post India: Rotavirus vaccine reduced severe rotavirus diarrhea by 40 percent in Phase 3 study appeared first on Outbreak News Today.